Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure- based virtual screening

被引:27
|
作者
Atatreh, Noor [1 ]
Ghattas, Mohammad A. [1 ]
Bardaweel, Sanaa K. [2 ]
Al Rawashdeh, Sara [1 ]
Al Sorkhy, Mohammad [1 ]
机构
[1] Al Ain Univ Sci & Technol, Dept Pharmaceut Sci, Coll Pharm, Al Ain, U Arab Emirates
[2] Univ Jordan, Dept Pharmaceut Sci, Sch Pharm, Amman 11942, Jordan
来源
关键词
protein-protein interaction; virtual screening; Mdm2; p53; anticancer; docking; pharmacophore; ELISA; P53-MDM2; INTERACTION; P53; PATHWAY; CANCER; DISCOVERY; DESIGN; POTENT;
D O I
10.2147/DDDT.S182444
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The tumor suppressor protein p53 plays an important role in preventing tumor formation and progression through its involvement in cell division control and initiation of apoptosis. Mdm2 protein controls the activity of p53 protein through working as ubiquitin E3 ligase promoting p53 degradation through the proteasome degradation pathway. Inhibitors for Mdm2-p53 interaction have restored the activity of p53 protein and induced cancer fighting properties in the cell. Purpose: The objective of this study is to use computer-aided drug discovery techniques to search for new Mdm2-p53 interaction inhibitors. Methods: A set of pharmacophoric features were created based on a standard Mdm , inhibitor and this was used to screen a commercial drug-like ligand library; then potential inhibitors were docked and ranked in a multi-step protocol using GLIDE. Top ranked ligands from docking were evaluated for their inhibition activity of Mdm2-p53 interaction using ELISA testing. Results: Several compounds showed inhibition activity at the submicromolar level, which is comparable to the standard inhibitor Nutlin-3a. Furthermore, the discovered inhibitors were evaluated for their anticancer activities against different breast cancer cell lines, and they showed an interesting inhibition pattern. Conclusion: The reported inhibitors can represent a starting point for further SAR studies in the future and can help in the discovery of new anticancer agents.
引用
收藏
页码:3741 / 3752
页数:12
相关论文
共 50 条
  • [31] Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models
    Bowman, Anna L.
    Nikolovska-Coleska, Zaneta
    Zhong, Haizhen
    Wang, Shaomeng
    Carlson, Heather A.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (42) : 12809 - 12814
  • [32] An update patent review of MDM2-p53 interaction inhibitors (2019-2023)
    Twarda-Clapa, Aleksandra
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2024, 34 (12) : 1177 - 1198
  • [33] MEDI 147-Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction
    Watson, Anna F.
    Golding, Bernard T.
    Griffin, Roger J.
    Hutton, Claire
    Liu, Junfeng
    Lu, Xiaohong
    Lunec, John
    Newell, David R.
    Valeur, Eric
    Hardcastle, Ian R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [34] Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models
    Bowman, Anna L.
    Nikolovska-Coleska, Zaneta
    Zhong, Haizhen
    Wang, Shaomeng
    Carlson, Heather A.
    Journal of the American Chemical Society, 2007, 129 (42): : 12809 - 12814
  • [35] Potent and Orally Active Small-Molecule Inhibitors of the MDM2-p53 Interaction
    Yu, Shanghai
    Qin, Dongguang
    Shangary, Sanjeev
    Chen, Jianyong
    Wang, Guoping
    Ding, Ke
    McEachern, Donna
    Qiu, Su
    Nikolovska-Coleska, Zaneta
    Miller, Rebecca
    Kang, Sanmao
    Yang, Dajun
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (24) : 7970 - 7973
  • [36] Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction
    Chessari, Gianni
    Hardcastle, Ian R.
    Ahn, Jong Sook
    Anil, Burcu
    Anscombe, Elizabeth
    Bawn, Ruth H.
    Bevan, Luke D.
    Blackburn, Timothy J.
    Buck, Ildiko
    Cano, Celine
    Carbain, Benoit
    Castro, Juan
    Cons, Ben
    Cully, Sarah J.
    Endicott, Jane A.
    Fazal, Lynsey
    Golding, Bernard T.
    Griffin, Roger J.
    Haggerty, Karen
    Harnor, Suzannah J.
    Hearn, Keisha
    Hobson, Stephen
    Holvey, Rhian S.
    Howard, Steven
    Jennings, Claire E.
    Johnson, Christopher N.
    Lunec, John
    Miller, Duncan C.
    Newell, David R.
    Noble, Martin E. M.
    Reeks, Judith
    Revill, Charlotte H.
    Riedinger, Christiane
    St Denis, Jeffrey D.
    Tamanini, Emiliano
    Thomas, Huw
    Thompson, Neil T.
    Vinkovic, Mladen
    Wedge, Stephen R.
    Williams, Pamela A.
    Wilsher, Nicola E.
    Zhang, Bian
    Zhao, Yan
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (07) : 4071 - 4088
  • [37] Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors
    Grigoreva, Tatyana A.
    Novikova, Daria S.
    Petukhov, Alexey V.
    Gureev, Maxim A.
    Garabadzhiu, Alexander V.
    Melino, Gerry
    Barlev, Nickolai A.
    Tribulovich, Vyacheslav G.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (23) : 5197 - 5202
  • [38] Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction
    Pettersson, Mariell
    Quant, Maria
    Min, Jaeki
    Iconaru, Luigi
    Kriwacki, Richard W.
    Waddell, M. Brett
    Guy, R. Kiplin
    Luthman, Kristina
    Grotli, Morten
    PLOS ONE, 2015, 10 (10):
  • [39] Targeting the MDM2-p53 interaction: evaluation of a novel, potent MDM2-p53 antagonist in patient-derived CLL cells
    Willmore, Elaine
    Aptullahoglu, Erhan
    Zhao, Yan
    Kyle, Suzanne
    Thomas, Huw
    Ahn, Maria
    Fazal, Lynsey
    Noble, Martin
    Hardcastle, Ian
    Howard, Steven
    Chessari, Gianni
    Lunec, John
    Wedge, Steve
    LEUKEMIA & LYMPHOMA, 2020, 61 : 81 - 81
  • [40] Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search
    Chen, Si
    Li, Xiang
    Yuan, Weirong
    Zou, Yan
    Guo, Zhongwu
    Chai, Yifeng
    Lu, Wuyuan
    RSC ADVANCES, 2017, 7 (16): : 9989 - 9997